JP2021522801A5 - - Google Patents
Info
- Publication number
- JP2021522801A5 JP2021522801A5 JP2020561908A JP2020561908A JP2021522801A5 JP 2021522801 A5 JP2021522801 A5 JP 2021522801A5 JP 2020561908 A JP2020561908 A JP 2020561908A JP 2020561908 A JP2020561908 A JP 2020561908A JP 2021522801 A5 JP2021522801 A5 JP 2021522801A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- fragment
- sequence
- cdrs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024059296A JP2024088696A (ja) | 2018-05-09 | 2024-04-02 | ヒトネクチン４に特異的な抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862668824P | 2018-05-09 | 2018-05-09 | |
| US62/668,824 | 2018-05-09 | ||
| PCT/IL2019/050508 WO2019215728A1 (en) | 2018-05-09 | 2019-05-06 | Antibodies specific to human nectin4 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024059296A Division JP2024088696A (ja) | 2018-05-09 | 2024-04-02 | ヒトネクチン４に特異的な抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021522801A JP2021522801A (ja) | 2021-09-02 |
| JP2021522801A5 true JP2021522801A5 (enExample) | 2022-05-13 |
| JP7879547B2 JP7879547B2 (ja) | 2026-06-24 |
Family
ID=66690730
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561908A Active JP7879547B2 (ja) | 2018-05-09 | 2019-05-06 | ヒトネクチン４に特異的な抗体 |
| JP2024059296A Withdrawn JP2024088696A (ja) | 2018-05-09 | 2024-04-02 | ヒトネクチン４に特異的な抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024059296A Withdrawn JP2024088696A (ja) | 2018-05-09 | 2024-04-02 | ヒトネクチン４に特異的な抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12077583B2 (enExample) |
| EP (1) | EP3790900A1 (enExample) |
| JP (2) | JP7879547B2 (enExample) |
| KR (2) | KR20250173584A (enExample) |
| CN (2) | CN119823267A (enExample) |
| AU (1) | AU2019264965B2 (enExample) |
| CA (1) | CA3097679A1 (enExample) |
| IL (1) | IL277858B2 (enExample) |
| WO (1) | WO2019215728A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| WO2020127377A1 (en) | 2018-12-21 | 2020-06-25 | Ose Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| TW202136287A (zh) | 2019-12-17 | 2021-10-01 | 法商Ｏｓｅ免疫治療公司 | 包含il-7變體之雙官能分子 |
| US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| CN113527486B (zh) * | 2020-04-21 | 2025-12-02 | 迈威(上海)生物科技股份有限公司 | 一种抗Nectin-4的抗体及其应用 |
| EP4147053B1 (en) | 2020-05-07 | 2026-01-28 | Institut Curie | Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy |
| IL298903A (en) * | 2020-06-18 | 2023-02-01 | Bioatla Llc | Antibodies against nectin-4 are conditionally active |
| KR20230060509A (ko) | 2020-09-04 | 2023-05-04 | 노바록 바이오테라퓨틱스 리미티드 | 넥틴-4 항체 및 이의 용도 |
| GEP20267876B (en) * | 2020-09-16 | 2026-03-25 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Anti-nectin-4 antibody, conjugate including same, and application thereof |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| WO2022148781A1 (en) | 2021-01-05 | 2022-07-14 | Institut Curie | Combination of mcoln activators and immune checkpoint inhibitors |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| MX2023011964A (es) | 2021-04-09 | 2024-01-08 | Ose Immunotherapeutics | Nuevo andamio para moléculas bifuncionales con propiedades mejoradas. |
| TW202302649A (zh) * | 2021-04-26 | 2023-01-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗ｎｅｃｔｉｎ－４抗體和抗ｎｅｃｔｉｎ－４抗體－藥物偶聯物及其醫藥用途 |
| KR20240026496A (ko) * | 2021-06-29 | 2024-02-28 | 엘피스 바이오파마슈티컬즈 | 항-넥틴4 항체 및 이를 포함하는 다중특이적 단백질 복합체 |
| KR20240040098A (ko) * | 2021-07-30 | 2024-03-27 | 알.피.쉐러 테크놀러지즈 엘엘씨 | 넥틴-4에 특이적인 항체 및 항체 접합체 및 이의 사용방법 |
| KR20240136924A (ko) * | 2021-08-27 | 2024-09-19 | 씨에스피씨 메가리스 바이오파마슈티칼 씨오., 엘티디. | 항 Nectin-4 항체, 약물 접합체 및 이의 제조방법 및 용도 |
| CN118696061A (zh) | 2022-01-12 | 2024-09-24 | 纳维再生科技股份有限公司 | Nectin细胞黏附分子4之特异性抗体及其用途 |
| US20250205353A1 (en) | 2022-03-23 | 2025-06-26 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing nectin-4 |
| WO2023198007A1 (en) * | 2022-04-11 | 2023-10-19 | Bj Bioscience Inc. | Anti-nectin-4 antibodies and bispecific antibodies |
| WO2023198011A1 (en) * | 2022-04-11 | 2023-10-19 | Bj Bioscience Inc. | Single domain anti-nectin-4 antibodies |
| CN116063498A (zh) * | 2022-04-27 | 2023-05-05 | 博际生物医药科技(杭州)有限公司 | 单域抗Nectin-4抗体 |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| EP4565610A1 (en) | 2022-08-02 | 2025-06-11 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| WO2024059733A2 (en) * | 2022-09-14 | 2024-03-21 | Fred Hutchinson Cancer Center | Chimeric antigen receptors binding nectin-4 |
| IL318911A (en) | 2022-09-20 | 2025-04-01 | Nectin Therapeutics Ltd | Humanized antibodies against NECTIN-4 and their drug conjugates |
| CN120435498A (zh) * | 2022-11-10 | 2025-08-05 | 世纪治疗股份有限公司 | 具有抗-nectin4嵌合抗原受体的基因工程化细胞及其用途 |
| WO2024147891A1 (en) * | 2023-01-03 | 2024-07-11 | Harpoon Therapeutics, Inc. | Nectin4 targeting trispecific protein for treatment of cancer |
| CN116381251B (zh) * | 2023-03-13 | 2024-06-25 | 柏定生物工程(北京)有限公司 | 一种肿瘤标志物诊断试剂盒及其诊断方法 |
| WO2024200820A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| JP2026512425A (ja) | 2023-03-30 | 2026-04-16 | オーエスイー・イミュノセラピューティクス | 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用 |
| CN119490590A (zh) * | 2023-05-24 | 2025-02-21 | 深圳市先康达生命科学有限公司 | 靶向人Nectin4蛋白的抗体或其片段和应用 |
| EP4725964A1 (en) * | 2023-06-08 | 2026-04-15 | Jiangsu Mabwell Health Pharmaceutical R&D Co., Ltd. | Antibody binding to nectin-4 and use thereof |
| WO2025068452A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025068461A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025132831A1 (en) | 2023-12-19 | 2025-06-26 | Universite D'aix-Marseille | N-heteroaryl derivatives and uses thereof for treating cancer |
| WO2025240789A1 (en) * | 2024-05-16 | 2025-11-20 | The Regents Of The University Of California | Chimeric antigen receptor targeting nectin4 |
| WO2025242836A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2025262250A1 (en) | 2024-06-20 | 2025-12-26 | Negio Therapeutics | Guanfacine derivatives and their uses |
| WO2026068705A1 (en) | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4198507A (en) | 1978-11-13 | 1980-04-15 | Hoffmann-La Roche Inc. | Theophylline magnesium salicylate |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| CA2128511C (en) | 1992-01-23 | 2006-11-07 | Andreas Pluckthun | Monomeric and dimeric antibody-fragment fusion proteins |
| JP3659261B2 (ja) | 1994-10-20 | 2005-06-15 | モルフォシス・アクチェンゲゼルシャフト | 組換体タンパク質の多機能性複合体への標的化ヘテロ結合 |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| WO1996037621A2 (en) | 1995-05-23 | 1996-11-28 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Multimeric proteins |
| US5719867A (en) | 1995-06-30 | 1998-02-17 | Scientific-Atlanta, Inc. | Plural telephony channel baseband signal demodulator for a broadband communications system |
| EP1103181A1 (de) | 1999-11-25 | 2001-05-30 | Novartis AG | Kombination der N-Phenyl-N'-Benzoyl Harnstoff Derivaten und Avermectin für Parasiten Kontrolle. |
| EP1481993A1 (en) | 2003-05-28 | 2004-12-01 | Xerion Pharmaceuticals AG | Modulation of the poliovirus receptor function |
| WO2006014999A2 (en) | 2004-07-27 | 2006-02-09 | Five Prime Therapeutics, Inc. | Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease |
| CA2672581A1 (en) * | 2006-12-14 | 2008-06-19 | Forerunner Pharma Research Co., Ltd. | Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same |
| US9399062B2 (en) * | 2011-01-18 | 2016-07-26 | Christopher D. Richardson | PVRL4 (Nectin4) is a receptor for measles virus |
| WO2014089169A2 (en) * | 2012-12-04 | 2014-06-12 | Oncomed Pharmaceuticals, Inc. | Immunotherapy with binding agents |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| CA2957722C (en) | 2014-08-19 | 2022-05-31 | Merck Sharp & Dohme Corp. | Anti-tigit antibodies |
| IL254039B2 (en) * | 2015-02-19 | 2023-12-01 | Compugen Ltd | Anti-pvrig antibodies and methods of use |
| US10946095B2 (en) | 2015-09-02 | 2021-03-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT) |
| EP3347048B1 (en) * | 2015-09-09 | 2020-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to nectin-4 and uses thereof |
| RU2756275C2 (ru) | 2016-03-01 | 2021-09-29 | Юссум Рисёрч Девелопмент Компани Оф Зэ Хибру Юниверсити Оф Иерусалим Лтд. | Антитела, специфические к рецептору полиовируса (pvr) человека |
| US11274160B2 (en) | 2017-03-02 | 2022-03-15 | INSERM (Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to Nectin-4 and uses thereof |
| WO2022056304A1 (en) * | 2020-09-10 | 2022-03-17 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using nectin-4 specific fusion proteins |
-
2019
- 2019-05-06 US US17/052,960 patent/US12077583B2/en active Active
- 2019-05-06 JP JP2020561908A patent/JP7879547B2/ja active Active
- 2019-05-06 CN CN202411898788.2A patent/CN119823267A/zh active Pending
- 2019-05-06 CN CN201980029788.XA patent/CN112088167B/zh active Active
- 2019-05-06 WO PCT/IL2019/050508 patent/WO2019215728A1/en not_active Ceased
- 2019-05-06 AU AU2019264965A patent/AU2019264965B2/en active Active
- 2019-05-06 EP EP19728137.1A patent/EP3790900A1/en active Pending
- 2019-05-06 CA CA3097679A patent/CA3097679A1/en active Pending
- 2019-05-06 KR KR1020257039502A patent/KR20250173584A/ko active Pending
- 2019-05-06 KR KR1020207031656A patent/KR102892725B1/ko active Active
-
2020
- 2020-10-07 IL IL277858A patent/IL277858B2/en unknown
-
2024
- 2024-04-02 JP JP2024059296A patent/JP2024088696A/ja not_active Withdrawn
- 2024-07-23 US US18/780,731 patent/US20240376202A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016281641B2 (en) | Novel PD-1 immune modulating agents | |
| JP2019511212A5 (enExample) | ||
| AU2019264965B2 (en) | Antibodies specific to human Nectin4 | |
| JP2022519341A5 (enExample) | ||
| JP2022515487A5 (enExample) | ||
| JP2021527431A5 (enExample) | ||
| JP2021531764A5 (enExample) | ||
| JP2020501531A5 (enExample) | ||
| IL253462B (en) | Cancer treatment with monoclonal antibodies against latency-associated peptide | |
| JP2018532383A5 (enExample) | ||
| RU2018134065A (ru) | Антитела, специфические к рецептору полиовируса (pvr) человека | |
| JP2019533719A5 (enExample) | ||
| JP2020527332A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| JP2018508483A5 (enExample) | ||
| CN108348521A (zh) | 用于治疗癌症的5-溴-2,6-二-(1h-吡唑-1-基)嘧啶-4-胺 | |
| FI3941946T3 (fi) | Klaudiini-6-vasta-aineita ja klaudiini-6-vasta-ainelääkekonjugaatteja | |
| JP2021512107A5 (enExample) | ||
| JP2022512713A5 (enExample) | ||
| JP2013519367A5 (enExample) | ||
| JP2022553922A5 (enExample) | ||
| JP2021520201A5 (enExample) | ||
| JP2015509960A5 (enExample) | ||
| JP2021533796A5 (enExample) | ||
| JP2025148452A5 (enExample) |